ARLINGTON, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), (“KALA” or the “Company”) today announced the successful completion of its ...

The latest update is out from KALA BIO ( (KALA)). KALA BIO has scheduled its next annual meeting of stockholders for January 30, 2026, with stockholder proposals due by December 27, 2025. The company ...

ARLINGTON, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA) ("KALA” or the "Company”), today announced the closing of its previously announced registered direct offering priced at ...

Investing.com -- Kala Pharmaceuticals Inc (NASDAQ:KALA) stock dropped 6.7% Friday after the company announced the closing of its previously announced registered direct offering that raised ...

KALA BIO, Inc. (NASDAQ: KALA) shares jumped 22.16% to $1.13 in after-hours trading on Wednesday. Check out the current price of KALA stock here. Securities and Exchange Commission filings indicate ...

ARLINGTON, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA) (“KALA” or the “Company”), today announced that it has entered into definitive agreements for the purchase of an ...

Kala Bio shares surged after the biopharmaceutical company said it had named David Lazar as chief executive and board chair, following the investor's purchase of $6 million in stock. Kala shares were ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An announcement from Kala Pharmaceuticals ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Arlington biotech has been ...

Shares of KALA BIO KALA have nosedived 88.3% in a month after the company announced the failure of a mid-stage study evaluating its only clinical pipeline candidate, KPI-012, for the treatment of ...

Kala Bio will stop developing its experimental treatment for a type of eye condition after it failed to meet the main goal in a mid-stage study, sending the drug developer's shares down 93% in ...

Sept 29 (Reuters) - Kala Bio (KALA.O), opens new tab will stop developing its experimental treatment for a type of eye condition after it failed to meet the main goal in a mid-stage study, sending the ...